Postoperative nausea and vomiting (PONV) are common and distressing complications following laparoscopic gynecologic surgery. This randomized controlled trial evaluated whether a single preoperative intravenous dose of dexamethasone reduces postoperative vomiting compared with placebo and explored patient-related risk factors associated with PONV.

Women undergoing elective laparoscopic gynecologic surgery were randomly assigned to receive dexamethasone (5 mg IV) or placebo at induction of anesthesia. The primary outcome was the incidence of postoperative vomiting within 24 hours, with secondary outcomes including nausea severity, rescue antiemetic use, and postoperative recovery parameters.

This single-blind randomized controlled trial evaluated the prophylactic efficacy of a single preoperative intravenous dose of dexamethasone for preventing postoperative vomiting in women undergoing elective laparoscopic gynecologic surgery. The study was conducted at Holy Family Hospital, Rawalpindi Medical University, Pakistan, between October 1, 2017, and March 31, 2018.

Eligible women aged 15-65 years were randomized in a 1:1 ratio to receive either dexamethasone 5 mg intravenously or placebo (normal saline) at induction of anesthesia. Perioperative anesthesia and postoperative care were standardized across groups. The primary outcome was the incidence of postoperative vomiting within 24 hours after surgery. Secondary outcomes included nausea severity, need for rescue antiemetics, postoperative opioid use, and recovery parameters such as time to oral intake and mobilization. An exploratory analysis assessed patient-related predictors of postoperative nausea and vomiting, including body mass index and prior history of PONV.

Inclusion Criteria:

1. Female patients aged 15-65 years
2. Scheduled for elective laparoscopic gynecologic surgery
3. Able to provide written informed consent (for minors, consent obtained from legal guardians)

Exclusion Criteria:

1. Prior laparoscopic surgery
2. Known hypersensitivity to corticosteroids
3. Opioid use within 24 hours preoperatively
4. Ischemic heart disease
5. Uncontrolled hypertension or diabetes mellitus
6. Ongoing antiemetic therapy
7. Conversion to open surgery
8. Body mass index (BMI) > 30 kg/m²

Individual participant data will not be shared publicly due to local institutional policies and consent limitations. De-identified aggregate data are available from the corresponding author upon reasonable request.